Search the Newsreel

Telos Update

Faruqi & Faruqi, LLP is investigating potential claims against Telos Corporation (NASDAQ: TLS) following a federal securities class action lawsuit. The lawsuit alleges that Telos and its executives made false or misleading statements regarding the commencement of TSA and CMS contracts, which significantly impacted …

Telos Corporation (TLS) Earnings Expected to Grow: Should You Buy?

Artelo Biosciences Market Sentiment

This article analyzes market sentiment for Artelo Biosciences (ARTL) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from four analysts with an average price target of $6, and notes a 4.8% declining short float. The report …

Telos Company Profile & Introduction

This document provides a company profile and introduction for Telos. It details information relevant to understanding the company's background and operations.

Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Telomir Pharmaceuticals Inc (TELO), highlighting its current valuation score of 6.89, which ranks 142 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, indicating it is significantly below its recent high and …

Telos Corporation (NASDAQ:TLS) Given Consensus Rating of "Hold" by Analysts

Telos Corporation (NASDAQ:TLS) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $7.10, significantly above its current share price of $4.36. Despite beating quarterly revenue and EPS expectations, the company remains unprofitable, with analysts projecting a full-year loss. …

Telos (NASDAQ:TLS) Trading Down 3.9% - Here's Why

Telos (NASDAQ:TLS) stock dropped 3.9% to $4.42, with trading volume 29% above average, despite exceeding quarterly earnings and revenue estimates. Analyst sentiment is mixed, with an average "Hold" rating and a target price of $7.10, although some analysts rate it a "Buy." Insider selling …

BlackRock, Inc. (NASDAQ: TLS) discloses 5.7% beneficial stake in Telos

BlackRock, Inc. has filed a Schedule 13G disclosing a 5.7% beneficial ownership stake in Telos Corp (TLS). The asset manager beneficially owns 4,266,646 shares of Telos common stock as of June 30, 2026, with sole voting power over 4,206,806 shares and sole dispositive power …

Telos Corp (TLS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Telos Corp (TLS), highlighting its current valuation score of 7.08 out of 10 in the Integrated Hardware & Software industry. It notes that the company's current P/E ratio is -12.42, which is significantly below its recent high …

ANTELOPUS Standalone June 2026 Net Sales at Rs 131.04 crore, up 158.82% Y-o-Y

Telos Corp (TLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Telos Corp (TLS), covering its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. As of July 28, 2026, Telos Corp's stock price is trading between a resistance level …

Price to earnings forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

This article provides a brief overview of the "Price to earnings forward" metric for Artelo Biosciences, Inc. (NASDAQ: ARTL). It appears to be a financial data snippet from a larger platform, indicating the period, value, and change for this specific financial ratio. The metadata …

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis

This article provides a detailed financial overview and news analysis for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including its current stock price, key financials, income statements, balance sheets, cash flow, and peer comparison. It also offers a company profile highlighting its focus on developing therapeutic …

TELO|Telomir Pharmaceuticals Inc|Price:1.210|Chg%:-0.040

Telomir Pharmaceuticals Inc. (TELO) is a preclinical-stage pharmaceutical company focused on developing Telomir-1, a novel small molecule designed to lengthen protective telomere caps to combat age-related conditions such as Progeria, Wilson's disease, and Alzheimer's. The company aims to commercialize Telomir-1, an orally dosed drug, …

Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL

This article provides access to the financial overview of Artelo Biosciences, Inc. (NASDAQ: ARTL) through TradingView. It highlights where to find financials, statements, and other fundamental data for the company. The content primarily serves as a gateway to financial data and analysis tools for …

Telomir Pharmaceuticals Inc (TELO) Income Statement

This article presents the quarterly and annual income statements for Telomir Pharmaceuticals Inc (TELO), detailing financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. The data spans from FY2022Q1 to FY2026Q1, highlighting the company's consistent losses across …

Antelopus Selan Energy shifts Payal Upadhyay to public shareholder

Antelopus Selan Energy profit jumps 42% q-o-q as prices power revenue

Telos Corporation (TLS) Q1 2026 Earnings: EPS Surges Past Estimates as Stock Declines - Forward EPS Estimate

Telomir Pharmaceuticals (TELO) awards director 50,000 options at $1.34 exercise price

Telomir Pharmaceuticals (TELO) has granted director Edward Clouston MacPherson 50,000 non-qualified stock options at an exercise price of $1.34 per share. The options, which vested immediately, were issued on April 16, 2026, under the company's 2023 Omnibus Incentive Plan and expire on April 16, …

Telos Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Telos Corp (TLS), a provider of cyber, cloud, and enterprise security solutions. It covers the company's background, business segments (Security Solutions and Secure Networks), key financial data, and market performance. The profile also lists company executives and …

Telos Corporation to Announce Second Quarter 2026 Financial Results on August 10, 2026

Telos Corporation (NASDAQ: TLS) will report its second-quarter 2026 financial results on Monday, August 10, 2026. Following the release, management will host a webcast at 9:30 a.m. ET to discuss the financial results and business outlook. An on-demand replay of the webcast will be …

Telomir Pharmaceuticals Inc (TELO) Institutional Confidence

This article from TradingKey provides an overview of Telomir Pharmaceuticals Inc (TELO)'s institutional confidence, highlighting its current stock performance and market capitalization. It details the institutional shareholdings and recent shareholder activity, including changes in holdings by key investors such as Aminov (Erez) and BlackRock …

Telos sets Aug. 10 webcast to discuss second-quarter results

Telos Corporation (NASDAQ: TLS) announced it will release its second-quarter 2026 financial results on Monday, August 10, 2026. The company will host a webcast at 9:30 a.m. ET to review the results and discuss the business outlook, with an on-demand replay available afterward. Past …

Telos Corp (TLS) Cash Flow

This article provides a detailed cash flow statement for Telos Corp (TLS), covering quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, …

Telos Corp (TLS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Telos Corp (TLS), identifying its major institutional and individual shareholders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for key investors. The report also lists …

Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split report for Telomir Pharmaceuticals Inc (TELO), noting that the company has distributed $0.00 in dividends over the past five years. It indicates that there is no historical dividend data available for the company. The page also …

Telos Corp TLS Balance Sheet

This article provides a detailed quarterly and annual balance sheet for Telos Corp (TLS), covering various financial metrics from current assets like cash and receivables to non-current assets, liabilities, and shareholders' equity over several fiscal years. It offers investors data points to evaluate the …

TLS|Telos Corp|Price:4.625|Chg%:+0.115

This article provides a comprehensive stock analysis of Telos Corp (TLS) by TradingKey, highlighting its healthy fundamentals, significant growth potential, and fair valuation. The analysis covers various dimensions including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment, with an overall …

Telomir Pharmaceuticals Inc (TELO) Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Telomir Pharmaceuticals Inc (TELO), detailing its operating, investing, and financing cash flows. It includes financial data from FY2022Q3 through FY2026Q1, along with explanations of key cash flow terms and how to interpret them …

Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO

This page provides financial information for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including an overview of its financials, statements, statistics, dividends, earnings, and segments. It also details the top segments and regional performance by source and country, with market data provided by ICE Data Services …

Artelo Biosciences Inc ARTL Cash Flow Statement

This article provides a detailed quarterly and annual cash flow statement for Artelo Biosciences Inc (ARTL), covering operating, investing, and financing activities across multiple fiscal years. It includes key financial figures and year-over-year percentage changes, enabling an evaluation of the company's financial health. The …

John B. Wood Discloses Investment at Telos Corporation with 9.1% Stake

John B. Wood, Chairman and CEO of Telos Corporation, disclosed a 9.1% ownership stake in the company. This disclosure, via a Schedule 13D filing on July 24, 2026, corrects a missed filing obligation from the company's 2020 IPO. Wood asserts his stake is held …

Telos Corporation (TLS) CEO John Wood details 6.8M-share stake

Telos Corporation CEO John Wood has reported a beneficial ownership of 6,815,139 shares of common stock, representing 9.1% of the company's outstanding shares as of July 24, 2026. This Schedule 13D filing indicates sole voting and dispositive power over these shares, acquired through equity …

ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040

Artelo Biosciences Inc. (ARTL) is a clinical-stage pharmaceutical company focused on developing therapies that modulate lipid-signaling pathways for various conditions. Despite facing a weak stock market performance recently, the company exhibits strong fundamentals and high growth potential with a fairly valued stock. Analysts currently …

Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), which has a current financial score of 6.88 out of 10, ranking 131st out of 155 in the Pharmaceuticals industry. The analysis indicates robust financial status but low operating efficiency. Key financial metrics …